





The work carried out in the research tenure has been accumulated in the form of thesis 
entitled as “UTILIZING QUINAZOLINONES FOR THE Ru-, Rh-, Pd-CATALYZED 
C–C, C–N, C–O BOND FORMATION REACTIONS: SYNTHESIS AND 
ANTICANCER ACTIVITIES OF N-HETEROCYCLES”. The main aim of this work 
was the functionalization of quinazolinones by fine-tuning transition metal-catalysis to obtain 
heterocycles of biological interest. Further, synthesis of 2,3-dihydroquinazolin-4(1H)-ones, 
(E)-3-aryl-1-(5-(2-arylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-ones and 
evaluation of their anticancer activity. The thesis has been divided into four chapters. 
CHAPTER-1: Describes the general introduction of transition metal-catalyzed cross-
coupling/annulation, carbenoid insertion, alkenylation and heteroarylation reactions. 
CHAPTER-2: Describes the ruthenium as a single catalyst for two steps: one-pot 
ruthenium(II)-catalyzed aerobic oxidative dehydrogenation of dihydroquinazolinones and 
cross-coupling/annulation to give N-fused polycyclic heteroarenes. 
CHAPTER-3: This chapter consists of two sections. 
SECTION-A: This section deals with the rhodium(II)-catalyzed carbenoid insertion of N-




SECTION -B: This section describes the palladium(II)-catalyzed direct O-alkenylation of 2-
arylquinazolinones with N-tosylhydrazones: an efficient route to O-alkenylquinazolines. 
CHAPTER-4: This chapter consists of two sections. 
SECTION-A: This section deals with convenient and scalable synthesis of 2,3- 
dihydroquinazolin-4(1H)-one derivatives and their anticancer activities. 
SECTION-B: This section illustrates palladium(0)-catalyzed direct C–H heteroarylation of 
2-arylimidazo [1,2-a]pyridines with (E)-1-(5-bromothiophen-2-yl)-3-arylprop-2-en-1-ones 
and their anticancer activity. 
CHAPTER-1 
General Introduction of Transition Metal-Catalyzed Cross-Coupling/Annulation, 
Carbenoid Insertion, Alkenylation and Heteroarylation Reactions. 
Introduction: Quinazolinone as a building block occurs widely in natural products that 
exhibit a broad range of useful biological and pharmacological activities. It is assigned as a 
privileged skeleton in drug discovery.
[1]
 The construction of new carbon–carbon and carbon–
heteroatom bonds is the most vital tool in organic chemistry, critical for the synthesis of 







 In this chapter, we discussed different types of transition metal-catalyzed cross- 
coupling/annulation, carbenoid insertion, alkenylation and heteroarylation reactions with 
examples and recent applications of these reactions. 
CHAPTER-2 
Ruthenium as a Single Catalyst for Two Steps: One-Pot Ruthenium(II)-Catalyzed 
Aerobic Oxidative Dehydrogenation of Dihydroquinazolinones and Cross-
Coupling/Annulation to give N-Fused Polycyclic Heteroarenes. [Asian J. Org. Chem. 
2015, 4, 462–469] 
Introduction: Transition metal-mediated C−H bond functionalizations for C−C and 
C−heteroatom bond formation has evolved as a powerful tool for constructing complex 
structures.
[3]
 Due to highly-attractive green and sustainable advantages, molecular oxygen 
finds increasing use in both the commodities chemical industry and the academic labs.  
Statement of problem: Ruthenium(II)-catalyzed alkynes annulations with directing group 
containing arenes reported thus far required the use of additional oxidants, such as copper(II) 




Results and Discussion: One-pot oxidative dehydrogenation of dihydroquinazolinones 
followed by cross-coupling/annulation with alkynes to access N-fused polycyclic 
heteroarenes was performed in the presence of [RuCl2(p-cymene)]2 (5 mol%), O2 (balloon), 
Na2CO3 (2 equiv) in DCE (2 mL) at 80 °C for 12 h. First, we investigated the 
dihydroquinazolinones scope (Scheme 1). Products (1-9) were obtained in good to excellent 
yields with excellent functional-group tolerance. Electron-rich substrates gave high yields. 
The structure of the product 6 was confirmed by single crystal X-ray diffraction. Moreover, 
6-chloro-2-phenyl-2,3-dihydroquinazolin-4(1H)-one derivatives bearing electron-neutral, -
donating and -withdrawing groups were tested (10-18). We further tested heterocyclic 
dihydroquinazolinones, corresponding products (19-24) were obtained in good to excellent 
yields (Scheme 2). Scope of alkynes was then investigated using A1 as the coupling partner 
(Scheme 3). Aryl alkynes (B2) as well as more challenging alkyl alkynes (B3-B5) are also 





A25 produced exclusively one product 29 in 85% yield. When unsymmetrical alkyne was 













respectively. For alkynes and dihydroquinazolinones, intermolecular competition 
experiments were conducted. Results revealed that the aromatic alkyne and 
dihydroquinazolinone with electron-donating group showed higher reactivity. Mechanistic 
investigations revealed that CONH group serves as directing group and is essential for the 
annulation process. Further in two steps one-pot process, oxidative dehydrogenation occurs 
first, followed by cross-coupling/annulation. Based on the experimental results, a plausible 
mechanism has been illustrated. 
In summary, ruthenium(II)-catalyzed, aerobic oxidative dehydrogenation, cross-
coupling/annulation via C−H/N−H bond activation of dihydroquinazolinones with alkynes in 
one-pot to access N-fused polycyclic compounds was described. 
CHAPTER-3 (Section-A) 
Rhodium(II)-Catalyzed Carbenoid Insertion of N-Tosylhydrazones into Amide N–H 
Bonds: An Efficient Approach to N
3
-Benzyl/Alkyl-2-arylquinazolinones. [Adv. Synth. 
Catal. 2016, 358, 81–89] 
Introduction: The transition metal-catalyzed insertion of metal-carbenoids into C–H or X–H 
(X = heteroatom) bonds represents an excellent and powerful method for the formation of C–
C or C–X bonds.
[4]
  
Statement of problem: Carbenoid insertion into N–H bonds is a direct and potentially 
powerful method of forming C–N bonds, which is an underexploited process with great 
potential for further development. 
Methodology used: 
 
Results and Discussion: Upon screening a variety of reaction conditions, we identified a 
standard condition as follows: A1 (0.25 mmol), B1 (0.3 mmol), K2CO3 (0.5 mmol), 
[Rh2(OAc)4] (1 mol%), in 1,4-dioxane at 90 °C for 4 h. We subsequently investigated the 
preparative scope of dihydroquinazolinones (A1-A16) with benzaldehyde derived N-
tosylhydrazone (B1) to afford the corresponding N
3
-benzyl-2-arylquinazolin-4(3H)-ones (1-
16) with good to excellent yields (Scheme 1). The structure of the product 4 was confirmed 
by single crystal X-ray diffraction. Next, the scope of N-tosylhydrazones (B2-B12) was 





(Scheme 2). The desired products (17-27) were isolated in good yields. We also conduct this 





Further, 2-isopropyl-2,3-dihydroquinazolin-4(1H)-one (A17), 3-phenyl-3,4-dihydro-2H-
benzo[e][1,2,4]thiadiazine 1,1-dioxide (A18) and disubstituted N-tosylhydrazone (B13) were 
chosen as the substrates (Scheme 3). All reactions proceeded smoothly to form desired 
products (28-30) in 78-81% yield.  
 
Scheme 3 
To elucidate the reaction mechanism, we conducted control experiments. Results 





dehydrogenation, and then insertion of rhodium-carbenoid into amide N–H bond would take 
place. A plausible reaction mechanism was illustrated. 
In summary, we have demonstrated a general strategy for direct synthesis of N
3
-
benzyl/alkyl-2-arylquinazolinones via rhodium(II)-carbenoid involved insertion of N-
tosylhydrazones into the amide N–H bonds of quinazolinones.  
CHAPTER-3 (Section-B) 
Palladium(II)-Catalyzed Direct O-Alkenylation of 2-Arylquinazolinones with N-
Tosylhydrazones: An Efficient Route to O-Alkenylquinazolines. [Chem. Commun. 2017, 
53, 1672–1675] 
Introduction: The quinazoline moiety, an abundant core of nitrogen-containing heterocycles, 
is exemplified as a privileged structure that exhibits diverse biological activities. N-
tosylhydrazones were utilized as versatile coupling partners for cross-coupling reactions.
[5]
  
Statement of problem: Direct synthesis of O-alkenylatedquinazolines starting from 2-aryl-




Results and Discussion: After extensive optimization studies, we identified a standard 





NNHTs Pd(OAc)2 (2.5 mol%)
PPh3 (5 mol%)
Cs2CO3 (1 equiv)






B1 R = C6H5 1 R = C6H5 (90%)
B2 R = 4-MeC6H4 2 R = 4-MeC6H4 (91%)
B3 R = 4-OMeC6H4 3 R = 4-OMeC6H4 (86%)
B4 R = o-FC6H4 4 R = o-FC6H4 (82%)
B5 R = m-MeC6H4 5 R = m-MeC6H4 (85%)
B6 R = 4-FC6H4 6 R = 4-FC6H4 (92%)
B7 R = 4-ClC6H4 7 R = 4-ClC6H4 (89%)
B8 R = 4-BrC6H4 8 R = 4-BrC6H4 (87%)
B9 R = 4-PhC6H4 9 R = 4-PhC6H4 (73%)
B10 R = 2-Naphthyl 10 R = 2-Naphthyl (69%)
B11 R = 2,4-diClC6H3 11 R = 2,4-diClC6H3 (82%)
B12 R = 3,5-diFC6H3 12 R = 3,5-diFC6H3 (89%)
B13 R = 4-CF3C6H4 13 R = 4-CF3C6H4 (78%)
B14 R = 4-NO2C6H4 14 R = 4-NO2C6H4 (68%)
B15 R = 2-Phenylethane 15 R = 2-Phenylethane (71%)
B16 R = Propane 16 R = Propane (68%)










Cs2CO3 (1 equiv.), in t-AmOH (3 mL), at 80 °C, open to air for 12 h. We then investigated 
the scope of N-tosylhydrazones (B1-B17). Aryl as well as aliphatic N-tosylhydrazones 
reacted smoothly, to give desired products (1-17) in 66-92% yields (Scheme 1). Next, the 
scope of 2-aryl-quinazolinones was examined using B1 as the olefin source (Scheme 2). The 
reaction is significantly affected by the position of substituent on the aromatic ring. It is 
noteworthy that chloro and bromo substituents are tolerated, which is advantageous for 
further transformations. Moreover, hetero aryl bearing quinazolinones also worked well in 
the reaction (26-27). 2-Phenylthieno[3,2-d]pyrimidin-4(3H)-one also successfully employed 
as substrate (29). Gram-scale synthesis of 1 was performed in excellent yield. Preliminary 
mechanistic experiments were conducted, a plausible mechanism was illustrated. 
In conclusion, we have developed an efficient Pd(II)-catalyzed direct O-alkenylation 
reaction of 2-aryl-quinazolinones with simple ketone-derived N-tosylhydrazones as the 
alkene source to give O-alkenylated quinazolines. 
CHAPTER-4 (Section-A) 
Convenient and Scalable Synthesis of 2,3-Dihydroquinazolin-4(1H)-one Derivatives and 
Their Anticancer Activities [Synth. Commun. 2015, 45, 1893–1901] 
Introduction: Cancer is a systemic disease characterized by uncontrolled growth of 
abnormal cells and is a leading cause of fatality worldwide.
[6]
 2,3-Dihydroquinazolin-4(1H)-
one derivatives are an important class of fused N-containing heterocycles with various 
biological, medicinal, and pharmacological activities. 
Statement of problem: Synthesis of 2,3-dihydroquinazolin-4(1H)-one derivatives requires 








Results and Discussion: We carried out the cyclocondensation reaction between 2-
aminobenzanilide (A1) and benzaldehyde (B1) under various conditions. It was found that 
0.5 mol% of InBr3 efficiently catalyzed the reaction. We extended the scope of this method 
by synthesizing an array of 2,3-dihydroquinazolin-4(1H)-one derivatives (1-25) bearing 
either electron-donating or -withdrawing groups on the aromatic ring (Scheme 1). Further, 
aliphatic aldehydes were also tested in the reaction (26 and 27). Finally, the reaction is 
accessible on a high scale (10 mmol of 2-aminobenzanilide and benzaldehyde), requiring 
only 60 min to achieve excellent yield of 92%. A plausible mechanism was illustrated to 







O InBr3 (0.5 mol%)









A1 X = H; R1 = Ph B1 R2 = C6H5 1 X = H; R
1 = Ph; R2 = C6H5 (94%)
A1 X = H; R1 = Ph B2 R2 = 4-MeC6H4 2 X = H; R
1 = Ph; R2 = 4-MeC6H4 (96%)
A1 X = H; R1 = Ph B3 R2 = 4-IsopropylC6H4 3 X = H; R
1 = Ph; R2 = 4-IsopropylC6H4 (97%)
A1 X = H; R1 = Ph B4 R2 = 4-MeOC6H4 4 X = H; R
1 = Ph; R2 = 4-MeOC6H4 (98%)
A1 X = H; R1 = Ph B5 R2 = 3,4-diMeOC6H3 5 X = H; R
1 = Ph; R2 = 3,4-diMeOC6H3 (95%)
A1 X = H; R1 = Ph B6 R2 = 3,4,5-triMeOC6H2 6 X = H; R
1 = Ph; R2 = 3,4,5-triMeOC6H2 (96%)
A1 X = H; R1 = Ph B7 R2 = 4-FC6H4 7 X = H; R
1 = Ph; R2 = 4-FC6H4 (96%)
A1 X = H; R1 = Ph B8 R2 = 2,4-diClC6H3 8 X = H; R
1 = Ph; R2 = 2,4-diClC6H3 (94%)
A1 X = H; R1 = Ph B9 R2 = 4-BrC6H4 9 X = H; R
1 = Ph; R2 = 4-BrC6H4 (97%)
A1 X = H; R1 = Ph B10 R2 = 4-PhC6H4 10 X = H; R
1 = Ph; R2 = 4-PhC6H4 (96%)
A1 X = H; R1 = Ph B11 R2 = 4-CNC6H4 11 X = H; R
1 = Ph; R2 = 4-CNC6H4 (93%)
A1 X = H; R1 = Ph B12 R2 = 1-Naphthyl 12 X = H; R1 = Ph; R2 = 1-Naphthyl (94%)
A2 X = Cl; R1 = H B1 R2 = C6H5 13 X = Cl; R
1 = H; R2 = C6H5 (97%)
A2 X = Cl; R1 = H B2 R2 = 4-MeC6H4 14 X = Cl; R
1 = H; R2 = 4-MeC6H4 (95%)
A2 X = Cl; R1 = H B3 R2 = 4-IsopropylC6H4 15 X = Cl; R
1 = H; R2 = 4-IsopropylC6H4 (96%)
A2 X = Cl; R1 = H B4 R2 = 4-MeOC6H4 16 X = Cl; R
1 = H; R2 = 4-MeOC6H4 (98%)
A2 X = Cl; R1 = H B5 R2 = 3,4-diMeOC6H3 17 X = Cl; R
1 = H; R2 = 3,4-diMeOC6H3 (96%)
A2 X = Cl; R1 = H B6 R2 = 3,4,5-triMeOC6H2 18 X = Cl; R
1 = H; R2 = 3,4,5-triMeOC6H2 (95%)
A2 X = Cl; R1 = H B7 R2 = 4-FC6H4 19 X = Cl; R
1 = H; R2 = 4-FC6H4 (94%)
A2 X = Cl; R1 = H B8 R2 = 2,4-diClC6H3 20 X = Cl; R
1 = H; R2 = 2,4-diClC6H3 (93%)
A2 X = Cl; R1 = H B9 R2 = 4-BrC6H4 21 X = Cl; R
1 = H; R2 = 4-BrC6H4 (96%)
A2 X = Cl; R1 = H B10 R2 = 4-PhC6H4 22 X = Cl; R
1 = H; R2 = 4-PhC6H4 (95%)
A2 X = Cl; R1 = H B11 R2 = 4-CNC6H4 23 X = Cl; R
1 =H; R2 = 4-CNC6H4 (93%)
A2 X = Cl; R1 = H B12 R2 = 1-Naphthyl 24 X = Cl; R1 =H; R2 = 1-Naphthyl (95%)
A2 X = Cl; R1 = H B13 R2 = 4-NO2C6H4 25 X = Cl; R
1 = H; R2 = 4-NO2C6H4 (94%)
A1 X = H; R1 = Ph B14 R2 = Butyl 26 X = H; R1 = Ph; R2 = Butyl (75%)
A1 X = H; R1 = Ph B15 R2 = Pentyl 27 X = H; R1 = Ph; R2 = Pentyl (79%)  
Scheme 1 
in vitro cytotoxicity against four different human cancer cell lines, i.e., lung cancer (A549), 
breast cancer (MCF7), cervical cancer (HeLa), and prostate cancer (DU145). Doxorubicin is 
used as a reference drug in this study. Compounds 24, 15, 21, and 14 exhibited promising 
